KG
GMAB icon

Kilter Group’s Genmab GMAB Stock Holding History

Kilter Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92K Buy
179
+161
+894% +$4.28K ﹤0.01% 674
2026
Q1 		$483 Buy
18
+1
+6% +$30 ﹤0.01% 1364
2025
Q4 		$524 Hold
17
– – ﹤0.01% 1190
2025
Q3 		$522 Buy
+17
New +$414 ﹤0.01% 1045

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kilter Group's GMAB Position: Q2 2026 in Review

Kilter Group increased its Genmab (GMAB) stake by 894% in Q2 2026, buying an estimated $4.28K and bringing the position to 179 shares worth $4.92K. The position accounts for ﹤0.01% of the portfolio, ranked #674.

Kilter Group first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Kilter Group held 179 shares of Genmab worth $4.92K as of Q2 2026.
  • Kilter Group bought 161 Genmab shares in Q2 2026, an estimated $4.28K.
  • Genmab made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #674 holding.
  • Kilter Group first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.